Literature DB >> 8492228

Expression of xenobiotic metabolizing enzymes in breast cancer.

G I Murray1, R J Weaver, P J Paterson, S W Ewen, W T Melvin, M D Burke.   

Abstract

We have studied the expression of different xenobiotic metabolizing enzymes in primary operable breast cancer of no special type. The expression of two forms of cytochrome P450, microsomal epoxide hydrolase, and three classes of glutathione S-transferase was investigated using immunohistochemistry. The tumours were characterized by consistent expression of microsomal epoxide hydrolase and by variable expression of the two forms of cytochrome P450 and the three types of glutathione S-transferase. Cytochrome P450 1A and cytochrome P450 3A were identified in 39 and 22 per cent of tumours, respectively. In each case, immunostaining was present only in areas of invasive carcinoma. Epoxide hydrolase was identified in 89 per cent of tumours and glutathione S-transferases pi, mu, and alpha were identified in 56, 65, and 44 per cent of tumours, respectively. Immunoreactivity for epoxide hydrolase and glutathione S-transferases was identified in both tumours and non-neoplastic breast tissue. The presence of different xenobiotic metabolizing enzymes may have a role in determining the intrinsic drug resistance of breast cancer to a variety of anti-cancer drugs, and the expression of these enzymes can readily be assessed using immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492228     DOI: 10.1002/path.1711690312

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach.

Authors:  Xinyan Zhang; Yan Li; Tomi Akinyemiju; Akinyemi I Ojesina; Phillip Buckhaults; Nianjun Liu; Bo Xu; Nengjun Yi
Journal:  Genetics       Date:  2016-11-09       Impact factor: 4.562

Review 2.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

3.  Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.

Authors:  K T Kivistö; E U Griese; P Fritz; A Linder; J Hakkola; H Raunio; P Beaune; H K Kroemer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

Review 4.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

5.  Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.

Authors:  G I Murray; V E Taylor; J A McKay; R J Weaver; S W Ewen; W T Melvin; M D Burke
Journal:  Int J Exp Pathol       Date:  1995-08       Impact factor: 1.925

6.  Xenobiotic metabolising enzyme expression in colonic neoplasia.

Authors:  J A McKay; G I Murray; R J Weaver; S W Ewen; W T Melvin; M D Burke
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

7.  Cytochrome P450 expression in oesophageal cancer.

Authors:  G I Murray; D Shaw; R J Weaver; J A McKay; S W Ewen; W T Melvin; M D Burke
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

8.  The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells.

Authors:  Jitka Poljaková; Tomáš Eckschlager; Jana Hřebačková; Jan Hraběta; Marie Stiborová
Journal:  Interdiscip Toxicol       Date:  2008-09

Review 9.  Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.

Authors:  Radka Václavíková; David J Hughes; Pavel Souček
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

10.  Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells.

Authors:  Xiao-Dan Zhao; Ni Dong; Hong-Tao Man; Zhong-Lin Fu; Mei-Hong Zhang; Shuang Kou; Shi-Liang Ma
Journal:  Biomed Rep       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.